The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand ...

Recent advances in immunotherapy and combination therapies are revolutionizing the treatment landscape for both metastatic ...

The current and future research in bladder cancer includes new single agents and combination regimens, new strategies for using currently available drugs and regimens, molecularly targeted ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to ...

Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of ...

and bladder cancer. National Institute of Diabetes and Digestive and Kidney Diseases. Urinary tract imaging. Point of Care Ultrasound Certification Academy. Introduction to point of care urinary ...

Now, when we think historically about the outcomes for cisplatin-ineligible metastatic urothelial cancer, the median survival for patients treated with gemcitabine and carboplatin in the EORTC ...

Lower abdominal visceral fat area (VFA), older age, and prolonged surgery are independent risk factors for developing postoperative neurogenic bladder (PONB) after rectal cancer surgery ...